Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press4110.17650/1994-4098-2013-0-1-2-52-59GYNECOLOGY. PROBLEMГИНЕКОЛОГИЯ. ПРОБЛЕМАPersistent trophoblastic tumorsПерсистирующие трофобластические опухолиTikhonovskayaM. N.ТихоновскаяМ. Н.
Russian Federation
rommary03@mail.ruBystritskayaD. A.БыстрицкаяД. А.
Russian Federation
KuznetsovV. V.КузнецовВ. В.
Russian Federation
MeshcheryakovaL. A.МещеряковаЛ. А.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва210520131-2525921072014210720142013https://ojrs.abvpress.ru/ojrs/article/view/41

Persistent trophoblastic tumors (PTT) are the most common trofhoblastic tumors, which develop in women when proliferative trophoblastic activ- ity remains after evacuation of hydatidiform mole. The term persistent trophoblastic disease (PTD) is also widely used in the world literature. When PTD develops, new tissue is often not obtained. PTD is defined as a plateau or rise of serum β-hCG concentrations in tree subsequent weekly blood samples for 2 consecutive weeks (1, 8, 15 measurement days), the detection of β-hCG rise 6 months after hydatidiform mole evacu- ation. β-hCG is a glycoprotein hormone produced by trophoblastic tissue and a key tumor marker of gestational trophoblastic disease (GTD) with almost 100 % sensitivity and specificity. A persistent trophoblastic tumor may have the histological features of invasive hydatidiform mole, cho- riocarcinoma or rare forms of trophoblastic disease. PTD is a fatal disease, which occurs in women of reproductive age. PTT is nowadays typi- cally treated with chemotherapy according to international standards for GTD management. In the case of early identification and adequate treatment of PTT the cure rates approach 100 %.

persistent trophoblastic tumorspersistent trophoblastic diseasehydatidiform moleперсистирующие трофобластические опухолиперсистирующая трофобластическая болезньпузырный занос1. Genest D.R., Berkowitz R., Fisher R.A. et al. Gestational trophoblastic disease. In: WHO Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Eds. F.A. Tavassoli, P. Devilee. Lion: IARC Press, 2003. Pр. 250–4.Genest D.R., Berkowitz R., Fisher R.A. et al. Gestational trophoblastic disease. In: WHO Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Eds. F.A. Tavassoli, P. Devilee. Lion: IARC Press, 2003. Pр. 250–4.2. Steigrad S.J. Epidemiology of gestational trophoblastic diseases. Best Pract Res Clin Obstet Gynaecol 2003;17(6):837–47.Steigrad S.J. Epidemiology of gestational trophoblastic diseases. Best Pract Res Clin Obstet Gynaecol 2003;17(6):837–47.3. Newlands E.S. Clinical management of trophoblastic disease in United Kingdom. Curr Obstet Gynaecol 1995;5(1):19–24.Newlands E.S. Clinical management of trophoblastic disease in United Kingdom. Curr Obstet Gynaecol 1995;5(1):19–24.4. Tsukamoto N., Iwasaka T., Kashimura Y. Gestational trophoblastic disease in women aged 50 or more. Gynaecol Oncol 1985;20(1):53–61.Tsukamoto N., Iwasaka T., Kashimura Y. Gestational trophoblastic disease in women aged 50 or more. Gynaecol Oncol 1985;20(1):53–61.5. Paradinas F.J., Browne P., Fisher R.A. et al. A clinical, histopathological and flowcytometric study of 149 complete moles, 146 partial moles and 107 non-molar hydropic abortions. Histopathology 1996;28(2):101–10.Paradinas F.J., Browne P., Fisher R.A. et al. A clinical, histopathological and flowcytometric study of 149 complete moles, 146 partial moles and 107 non-molar hydropic abortions. Histopathology 1996;28(2):101–10.6. Kajii S.D., Ohama K. Androgenetic origin of hydatidiform mole. Nature 1977;268(5621):633–4.Kajii S.D., Ohama K. Androgenetic origin of hydatidiform mole. Nature 1977;268(5621):633–4.7. Lawler S.D., Pickthall V.J., Fisher R.A. et al. Genetic studies of complete and partial hydatidiform moles. Lancet 1979;2(8142):580.Lawler S.D., Pickthall V.J., Fisher R.A. et al. Genetic studies of complete and partial hydatidiform moles. Lancet 1979;2(8142):580.8. Ohama K., Kajii T., Okamoto E. et al. Dispermic origin of XY hydatidiform moles. Nature 1981;292(5823):551–2.Ohama K., Kajii T., Okamoto E. et al. Dispermic origin of XY hydatidiform moles. Nature 1981;292(5823):551–2.9. Bentley R.C. Pathology of gestational trophoblastic disease. Clin Obstet Gynecol 2003;46(3):513–22.Bentley R.C. Pathology of gestational trophoblastic disease. Clin Obstet Gynecol 2003;46(3):513–22.10. Matsuda T., Wake N. Genetics and molecular markers in gestational trophoblastic disease with special reference to their clinical application. Best Pract Res Clin Obstet Gynaecol 2003;17(6):827–36.Matsuda T., Wake N. Genetics and molecular markers in gestational trophoblastic disease with special reference to their clinical application. Best Pract Res Clin Obstet Gynaecol 2003;17(6):827–36.11. Berkowitz R.S., Goldstein D.P. Chorionic tumors. N Engl J Med 1996;335(23):1740–8.Berkowitz R.S., Goldstein D.P. Chorionic tumors. N Engl J Med 1996;335(23):1740–8.12. Soto-Wright V., Bernstein M., Goldstein D.P., Berkowitz R.S. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol 1995;86(5):775–9.Soto-Wright V., Bernstein M., Goldstein D.P., Berkowitz R.S. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol 1995;86(5):775–9.13. Gemer O., Segal S., Kopmar A., Sassoon E. The current clinical presentation of complete molar pregnancy. Arch Gynecol Obstet 2000;264(1):33–4.Gemer O., Segal S., Kopmar A., Sassoon E. The current clinical presentation of complete molar pregnancy. Arch Gynecol Obstet 2000;264(1):33–4.14. Bagshawe K.D., Lawler S.D., Paradinas F.J. et al. Gestational trophoblastic tumors following initial diagnosis of partial hydatidiform mole. Lancet 1990;335(8697):1074–6.Bagshawe K.D., Lawler S.D., Paradinas F.J. et al. Gestational trophoblastic tumors following initial diagnosis of partial hydatidiform mole. Lancet 1990;335(8697):1074–6.15. Berkowitz R.S., Goldstein D.P., Bernstein M.R. Natural history of partial molar pregnancy. Obstat Gynecol 1985;66(5):677–81.Berkowitz R.S., Goldstein D.P., Bernstein M.R. Natural history of partial molar pregnancy. Obstat Gynecol 1985;66(5):677–81.16. Goto S., Yamada A., Ishizuka T., Tomoda Y. Development of postmolar trophoblastic disease after partial molar pregnancy. Gynecol Oncol 1993;48(2):165–70.Goto S., Yamada A., Ishizuka T., Tomoda Y. Development of postmolar trophoblastic disease after partial molar pregnancy. Gynecol Oncol 1993;48(2):165–70.17. Rice L.W., Berkowitz R.S., Lage J.M. et al. Persistent gestational trophoblastic tumor after partial hydatidiform mole. Gynecol Oncol 1990;36(3):358–62.Rice L.W., Berkowitz R.S., Lage J.M. et al. Persistent gestational trophoblastic tumor after partial hydatidiform mole. Gynecol Oncol 1990;36(3):358–62.18. Berkowitz R.S., Goldstein D.P. Gestational trophoblastic disease. Cancer 1995;76(10 Suppl):2079–85.Berkowitz R.S., Goldstein D.P. Gestational trophoblastic disease. Cancer 1995;76(10 Suppl):2079–85.19. Smith H.O., Kim S.J. Epidemiology. Hancock B.W., Newlands E.S., Berkowitz R., Cole L. (eds.). Gestational Trophoblastic Disease, online book. 2003. Рp. 39–76. http://www.isstd.org.Smith H.O., Kim S.J. Epidemiology. Hancock B.W., Newlands E.S., Berkowitz R., Cole L. (eds.). Gestational Trophoblastic Disease, online book. 2003. Рp. 39–76. http://www.isstd.org.20. Matsuura J., Chiu D., Jacobs P.A., Szulman A.E. Complete hydatidiform mole in Hawaii an epidemiological study. Genet Epidemiol 1984;1(3):271–84.Matsuura J., Chiu D., Jacobs P.A., Szulman A.E. Complete hydatidiform mole in Hawaii an epidemiological study. Genet Epidemiol 1984;1(3):271–84.21. Kerkmeijer L.G., Wielsma S., Massuger L.F. et al. Recurrent gestational trophoblastic disease after HCG normalization following hydatidiform mole in the Netherlands. Gynecol Oncol 2007;106(1):142–6.Kerkmeijer L.G., Wielsma S., Massuger L.F. et al. Recurrent gestational trophoblastic disease after HCG normalization following hydatidiform mole in the Netherlands. Gynecol Oncol 2007;106(1):142–6.22. Wolfberg A.J., Feltmate C., Goldstein D.P. et al. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy. Obstet Gynecol 2004;104(3):551–4.Wolfberg A.J., Feltmate C., Goldstein D.P. et al. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy. Obstet Gynecol 2004;104(3):551–4.23. Dutch Society for Obstetrics and Gynecology. Richtlijn Basis Prenatale Zorg 1.0 (Guideline basic prenatal care). Available at: http://www. nvog.nl. Retrieved 1st September 2008.Dutch Society for Obstetrics and Gynecology. Richtlijn Basis Prenatale Zorg 1.0 (Guideline basic prenatal care). Available at: http://www. nvog.nl. Retrieved 1st September 2008.24. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynаecol Obstet 2002;77(3):285–7.FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynаecol Obstet 2002;77(3):285–7.25. TNM Classification of Malignant Tumors. 7th ed. Eds. L.H. Sobin, M.K. Gospodarowicz, Ch. Wittekind. New York: Wiley-Blackwell, 2009.TNM Classification of Malignant Tumors. 7th ed. Eds. L.H. Sobin, M.K. Gospodarowicz, Ch. Wittekind. New York: Wiley-Blackwell, 2009.26. Ngan H.Y.S., Bender H., Benedet J.L. et al.; FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynаecol Obstet 2003;83(Suppl 1):175–7.Ngan H.Y.S., Bender H., Benedet J.L. et al.; FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynаecol Obstet 2003;83(Suppl 1):175–7.27. Lurian L.R. Treatment of Metastatic Gestational Trophoblastic Tumors. In: Hancock B.W., Newlands E.S., Berkowitz R. Gestational Trophoblastic Disease. First ed. London: Chapman&Hall, 1997. Рp. 199–209.Lurian L.R. Treatment of Metastatic Gestational Trophoblastic Tumors. In: Hancock B.W., Newlands E.S., Berkowitz R. Gestational Trophoblastic Disease. First ed. London: Chapman&Hall, 1997. Рp. 199–209.28. McNeish I.A., Strickland S., Holden L. et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002;20(7):1838–44.McNeish I.A., Strickland S., Holden L. et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002;20(7):1838–44.29. Matsui H., Suzuka K., Yamazawa K. et al. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol Oncol 2005;96(3):616–20.Matsui H., Suzuka K., Yamazawa K. et al. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol Oncol 2005;96(3):616–20.30. Blagden S.P., Foskett M.A., Fisher R.A. et al. The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumors. Br J Cancer 2002;86(1):26–30.Blagden S.P., Foskett M.A., Fisher R.A. et al. The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumors. Br J Cancer 2002;86(1):26–30.31. Bower M., Newlands E.S., Holden L. et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997;15(7):2636–43.Bower M., Newlands E.S., Holden L. et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997;15(7):2636–43.32. Goldstein D.P., Berkowitz R.S., Bernstein M.R. Management of molar pregnancy. J Reprod Med 1981;26(4):208–12.Goldstein D.P., Berkowitz R.S., Bernstein M.R. Management of molar pregnancy. J Reprod Med 1981;26(4):208–12.33. Niemann I., Petersen L.K., Hanses E.S., Sunde L. Predictors of low risk of persistent trophoblastic disease in molar pregnancies. Obstet Gynecol 2006;107(5):1006–11.Niemann I., Petersen L.K., Hanses E.S., Sunde L. Predictors of low risk of persistent trophoblastic disease in molar pregnancies. Obstet Gynecol 2006;107(5):1006–11.34. Калинин А.В. Клинико-морфологиче- ские особенности пузырного заноса и его прогноз. Дис. ... канд. мед. наук. М., 1982.Калинин А.В. Клинико-морфологиче- ские особенности пузырного заноса и его прогноз. Дис. ... канд. мед. наук. М., 1982.35. Kim D.S., Moon H., Kim K.T. et al. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol 1986;67(5):690–4.Kim D.S., Moon H., Kim K.T. et al. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol 1986;67(5):690–4.36. Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med 2001;46(2):110–6.Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med 2001;46(2):110–6.37. Kashimura Y., Kashimura M., Sugimori H. et al. Prophylactic chemotherapy for hydatidiform mole. Five to 15 years follow-up. Cancer 1986;58(3):624–9.Kashimura Y., Kashimura M., Sugimori H. et al. Prophylactic chemotherapy for hydatidiform mole. Five to 15 years follow-up. Cancer 1986;58(3):624–9.38. Park T.K., Kim S.N., Lee S.K. Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy. Yonsei Med J 1996;37(6):412–9.Park T.K., Kim S.N., Lee S.K. Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy. Yonsei Med J 1996;37(6):412–9.39. Fisher P.M., Hancock B.W. Gestational trophoblastic diseases and their treatment. Cancer Treat Rev 1997;23(1):1–16.Fisher P.M., Hancock B.W. Gestational trophoblastic diseases and their treatment. Cancer Treat Rev 1997;23(1):1–16.40. Pezeshki M., Hancock B.W., Silcocks P. et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol 2004;95(3):423–9.Pezeshki M., Hancock B.W., Silcocks P. et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol 2004;95(3):423–9.41. Royal College of Obstetricians and Gynaecologists. The Management of Gestational Trophoblastic Neoplasia, guideline no 38. Available from: http://www.rcog.org.uk.Royal College of Obstetricians and Gynaecologists. The Management of Gestational Trophoblastic Neoplasia, guideline no 38. Available from: http://www.rcog.org.uk.42. Schlaerth J.B., Morrow C.P., Rodriguez M. Diagnostic and therapeutic curettage in gestational trophoblastic disease. Am J Obstet Gynecol 1990;162(6):1465–70.Schlaerth J.B., Morrow C.P., Rodriguez M. Diagnostic and therapeutic curettage in gestational trophoblastic disease. Am J Obstet Gynecol 1990;162(6):1465–70.43. Jones W.B., Lewis J.L. Integration of surgery and other techniques in the management of trophoblastic malignancy. Obstet Gynecol Clin North Am 1988;15(3):565–76.Jones W.B., Lewis J.L. Integration of surgery and other techniques in the management of trophoblastic malignancy. Obstet Gynecol Clin North Am 1988;15(3):565–76.44. Bentash N., Ansari S., Sarvi F. Successful pregnancy after localized resection of perforated uterus in choriocarcinoma and a literature review. Int J Gynecol Cancer 2006;16 Suppl 1:445–8.Bentash N., Ansari S., Sarvi F. Successful pregnancy after localized resection of perforated uterus in choriocarcinoma and a literature review. Int J Gynecol Cancer 2006;16 Suppl 1:445–8.45. Leiserowitz G.S., Webb M.J. Treatment of placental site trophoblastic tumor hysterotomy and uterine reconstruction. Obstet Gynecol 1996;88(4 Pt 2):696–9.Leiserowitz G.S., Webb M.J. Treatment of placental site trophoblastic tumor hysterotomy and uterine reconstruction. Obstet Gynecol 1996;88(4 Pt 2):696–9.46. Мещерякова Л.А. Злокачественные трофобластические опухоли: современная диагностика, лечение и прогноз. Дис. ... д-ра мед. наук. М., 2005.Мещерякова Л.А. Злокачественные трофобластические опухоли: современная диагностика, лечение и прогноз. Дис. ... д-ра мед. наук. М., 2005.47. Hanna R.K., Soper J.T. The role of surgery and radiation therapy in the management of gestational trophoblastic disease. Oncologist 2010;15(6):593–600.Hanna R.K., Soper J.T. The role of surgery and radiation therapy in the management of gestational trophoblastic disease. Oncologist 2010;15(6):593–600.48. Hancock B.W. Staging and classification of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 2003;17(6):869–83.Hancock B.W. Staging and classification of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 2003;17(6):869–83.49. Ross G.T., Goldstein D.P., Hertz R. et al. Sequential use of methotrexate and actinomycin D in the treatment of metastatic choriocarcinoma and related trophoblastic diseases in women. Am J Obstet Gynecol 1965;93:223–9.Ross G.T., Goldstein D.P., Hertz R. et al. Sequential use of methotrexate and actinomycin D in the treatment of metastatic choriocarcinoma and related trophoblastic diseases in women. Am J Obstet Gynecol 1965;93:223–9.50. Hammond C.B., Borchert L.C., Tyrey L. et al. Treatment of metastatic trophoblastic disease: good and poor prognosis. Am J Obstet Gynecol 1973;115(4):451–7.Hammond C.B., Borchert L.C., Tyrey L. et al. Treatment of metastatic trophoblastic disease: good and poor prognosis. Am J Obstet Gynecol 1973;115(4):451–7.51. Soper J.T., Evans A.C., Conaway M.R. et al. Evaluation of prognostic factors and staging in gestational trophoblastic tumor. Obstet Gynecol 1994;84(6):969–73.Soper J.T., Evans A.C., Conaway M.R. et al. Evaluation of prognostic factors and staging in gestational trophoblastic tumor. Obstet Gynecol 1994;84(6):969–73.52. Azab M.B., Pejovic M.H., Theodore C. et al. Prognostic factors in gestational trophoblastic tumors. A multivariate analysis. Cancer 1988;62(3):585–92.Azab M.B., Pejovic M.H., Theodore C. et al. Prognostic factors in gestational trophoblastic tumors. A multivariate analysis. Cancer 1988;62(3):585–92.53. Brewer J.I., Eckman T.R., Dolkart R.E. et al. Gestational trophoblastic disease. A comparative study of the results of therapy in patients with invasive mole and with choriocarcinoma. Am J Obstet Gynecol 1971;109(2):335–40.Brewer J.I., Eckman T.R., Dolkart R.E. et al. Gestational trophoblastic disease. A comparative study of the results of therapy in patients with invasive mole and with choriocarcinoma. Am J Obstet Gynecol 1971;109(2):335–40.54. Dorreen M.S., Pennington G.W., Millar D.R. et al. Results of low-dose methotrexate treatment of persistent gestational trophoblastic disease in Sheffield 1980–1987. Acta Oncol 1988;27(5):551–6.Dorreen M.S., Pennington G.W., Millar D.R. et al. Results of low-dose methotrexate treatment of persistent gestational trophoblastic disease in Sheffield 1980–1987. Acta Oncol 1988;27(5):551–6.55. Bagshawe K.D., Dent J., Newlands E.S. et al. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumors. Br J Obstet Gynaecol 1989;96(7):795–802.Bagshawe K.D., Dent J., Newlands E.S. et al. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumors. Br J Obstet Gynaecol 1989;96(7):795–802.56. Khan F., Everard J., Ahmed S. et al. Low- risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer 2003;89(12):2197–201.Khan F., Everard J., Ahmed S. et al. Low- risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer 2003;89(12):2197–201.57. Newlands E.S., Bagshawe K.D., Begent R.H. Results with the EMA-CO regimen in high-risk gestational trophoblastic tumors, 1979 to 1989. Br J Obstet Gynaecol 1991;98(6):550–7.Newlands E.S., Bagshawe K.D., Begent R.H. Results with the EMA-CO regimen in high-risk gestational trophoblastic tumors, 1979 to 1989. Br J Obstet Gynaecol 1991;98(6):550–7.58. Dobson L.S., Lorigan P.C., Coleman R.E., Hancock B.W. Persistent gestational trophoblastic disease: Results of MEA as first- line chemotherapy in high risk disease and EA as second-line therapy for low risk disease. Br J Cancer 2000;82(9):1547–52.Dobson L.S., Lorigan P.C., Coleman R.E., Hancock B.W. Persistent gestational trophoblastic disease: Results of MEA as first- line chemotherapy in high risk disease and EA as second-line therapy for low risk disease. Br J Cancer 2000;82(9):1547–52.